Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the… Read more
Market Cap & Net Worth: Longboard Pharmaceuticals Inc (LBPH)
Longboard Pharmaceuticals Inc (NASDAQ:LBPH) has a market capitalization of $2.07 Billion ($2.07 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5837 globally and #3383 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Longboard Pharmaceuticals Inc's stock price $59.98 by its total outstanding shares 34436200 (34.44 Million).
Longboard Pharmaceuticals Inc Market Cap History: 2021 to 2024
Longboard Pharmaceuticals Inc's market capitalization history from 2021 to 2024. Data shows growth from $168.05 Million to $2.07 Billion (40.63% CAGR).
Longboard Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Longboard Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LBPH by Market Capitalization
Companies near Longboard Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Longboard Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Longboard Pharmaceuticals Inc Historical Marketcap From 2021 to 2024
Between 2021 and today, Longboard Pharmaceuticals Inc's market cap moved from $168.05 Million to $ 2.07 Billion, with a yearly change of 40.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $2.07 Billion | +894.69% |
| 2023 | $207.65 Million | +84.97% |
| 2022 | $112.26 Million | -33.20% |
| 2021 | $168.05 Million | -- |
End of Day Market Cap According to Different Sources
On Dec 12th, 2025 the market cap of Longboard Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.07 Billion USD |
| MoneyControl | $2.07 Billion USD |
| MarketWatch | $2.07 Billion USD |
| marketcap.company | $2.07 Billion USD |
| Reuters | $2.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.